FDX1 and melanoma: More importantly, the immunotherapy data suggested that FDX1 can serve as a potential predictor for the assessment of immunotherapy efficacy in KIRC, with higher FDX1 expression levels leading to better immunotherapy efficacy, which was confirmed in two other melanoma cohorts (7, 24).